No Prescription |
 |
 | ||
|
Norlevo Plan B |
|
| ||
No Prescription » Prescription Drugs 12 » Norlevo Plan B This medication is used in women to prevent pregnancy after birth control failure (e.g. broken condom) or unprotected sex. It is a progestin hormone that prevents pregnancy by preventing the release of an egg (ovulation) and changing the womb and cervical mucus to make it more difficult for an egg to meet sperm (fertilization) or attach to the wall of the womb (implantation).Using this medication will not stop an existing pregnancy or protect you against sexually transmitted diseases (e.g. HIV gonorrhea chlamydia).This medication should not be used as a regular form of birth control. Buy Norlevo Plan B and other Prescription Drugs 12 products online at Medstore. Buy Online at Medstore - Click Here!
About Norlevo Plan B: Product Type: Prescription Drugs 12 Norlevo ( Plan B Generic Levonorgestrel ) Norlevo (Plan B Generic Levonorgestrel) Plan B Generic Levonorgestrel 750mcg Plan B Generic Levonorgestrel Norlevo
View more Prescription Drugs 12 No Prescription: NEW YORK, Oct. 5, 2011 /PRNewswire via COMTEX/ -- Reportlinker.com announces that a new market research report is available in its catalogue: European Pharmaceutical Market: Strategic Assessments of Leading Suppliers http://www.reportlinker.com/p0651431/European-Pharmaceutical-Market-Strategic-Assessments-of-Leading-Suppliers.html #utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication This report provides industry executives with strategically significant competitor information and analysis of the leading players in the European pharmaceutical market. The report provides a worldwide strategic overview of the pharmaceutical market, including: Sales forecast for major product segments: ethical, OTC, generics. Sales forecast for major drug categories: cardiovascular, gastrointestinal, antibiotic, CNS, respiratory, musculoskeletal, hormonal/genitourinary, dermatological, oncological, ophthalmic, and others. In addition, the report reviews major regulatory, technological, economic, demographic, and social trends with potentially significant impact on the market during the next five years, including discussion of such key issues as pricing, industry consolidation, market globalization, growing R&D cost, generics, as well as advances in genomics, proteomics, drug screening, tissue engineering, bioinformatics, and other technologies. The companies analyzed in this report include Abbott, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Pfizer, Roche, Sanofi-Aventis and Wyeth.
| ||
